Navigation Links
Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
Date:4/29/2008

- Subsequent Phase 1b study planned for mid 2008 with Phase 2 development

to begin late in 2008 or in early 2009 -

SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 proof-of-concept trial (n=30) of NU172, demonstrating that the thrombin-inhibitor achieved rapid onset and offset of anticoagulation after a single bolus dose with a favorable safety profile.

"There is a significant need for anticoagulants with fewer side effects and more predictable dosing than treatments currently available today," said David J. Schneider, M.D., professor of medicine and director of cardiology and vascular biology at the University of Vermont. "NU172 represents a new approach to anticoagulation for medical and surgical procedures through its potential to produce rapid and predictable onset of anticoagulation followed by rapid reversal once the infusion is discontinued."

The single-center, Phase 1 trial examined the safety, tolerability and pharmacokinetics of escalating bolus doses of NU172 in normal, healthy volunteers. In the trial, NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time (ACT). The 2.00 mg/kg bolus dose of NU172 achieved target ACTs of approximately 400 seconds. Upon withdrawal of NU172 the ACT showed a rapid return toward baseline with a plasma half-life of NU172 of approximately 10 minutes. No serious adverse events occurred in the trial.

"We are very encouraged by these findings and NU172's potential to address the need for rapid onset and offset of anticoagulation in medical procedures such as coronary artery bypass graft surgery and percutaneous coronary intervention,"
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
2. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
3. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
4. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
5. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
6. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
7. XTENT Announces First Quarter 2008 Financial Results
8. Neuralstem Announces Issuance of Core Technology Patent in Europe
9. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
10. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/11/2014)... Ohio (PRWEB) July 11, 2014 As ... 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of ... blood sugar, abdominal issues and even death from the ... , According to the Times report , a ... in 2013 reported by patients was almost 14% of ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Europe is one of the largest consumers of ... land area. The agricultural sector is a significant user ... of the total water use. The scale and importance ... but far from negligible in most northern ones. , ... of the water use in most countries, while in ...
Breaking Medicine News(10 mins):Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... the surgical treatment of retinal hemorrhages or injuries. The purpose ... to the wall of the eye. There is a risk ... at high altitudes, or under nitrous oxide anesthesia. This expansion ... for weeks after the surgical procedure. , In order to ...
... with a FREE Box of Healthy ... Feb. 25 Every four years, Leap Day,gives us an extra ... you to use that extra day -- which is also the ... help people take,a small leap to healthier eating, the makers of ...
... University of Maryland at College Park have discovered that ... with elevated zinc level, at the high end of ... cell growth, up-regulation of growth arrest and DNA damage-induced ... G2/M cell cycle progression. The research, published in the ...
... who are highly anxious about their skin condition say they ... to new research at the University of Bath (UK). , ... 50 young to middle-aged adults recruited from a national acne ... less likely to participate in sport or exercise, acne sufferers ...
... with Accumulator(R) Variable ... Annuity, ... in retirement, AXA Equitable Life,Insurance Company is offering a new way to ... company,s top-selling,Accumulator(R) variable annuity provides for a minimum 200% benefit base,guarantee if ...
... continues to add,new companies to their customer ... licenses. In the last year, Billian,s HealthDATA ... to provide their,customers, with meticulously researched, cutting-edge ... current information to guide informed,decisions about the ...
Cached Medicine News:Health News:'Free For All' on Leap Day to Get Hearts Pumping! 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 3Health News:Acne may prevent people from participating in sport and exercise, says research 2Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 2Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 3Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 4Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 2Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 3
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... The FLEXIPATH Flexible Surgical ... solid or mechanical obturator and ... designed to prevent puncture or ... flexible sleeve has securing holes ...
Medicine Products: